Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTA vs PEMETREXED FOR INJECTION
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Pemetrexed is a folate analog metabolic inhibitor that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent de novo synthesis of thymidine and purine nucleotides, thereby disrupting DNA and RNA synthesis.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Malignant pleural mesothelioma in combination with cisplatin for unresectable or patients who are not candidates for curative surgery,Non-small cell lung cancer (NSCLC), first-line treatment in combination with cisplatin for nonsquamous histology,NSCLC maintenance therapy for nonsquamous histology after platinum-based therapy,NSCLC second-line treatment for nonsquamous histology
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
500 mg/m² IV over 10 minutes on Day 1 of each 21-day cycle, in combination with cisplatin 75 mg/m² IV over 2 hours starting 30 minutes after pemetrexed completion. Administer folic acid 350-1000 µg po daily starting 7 days before first dose and continuing until 21 days after last dose, vitamin B12 1000 µg IM 7 days before first dose and every 3 cycles thereafter, and dexamethasone 4 mg po twice daily on day before, day of, and day after pemetrexed.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
The terminal elimination half-life is approximately 3-4 hours in patients with normal renal function (creatinine clearance ≥90 m L/min). In patients with impaired renal function (creatinine clearance 45-79 m L/min), the half-life may be prolonged to 4-5 hours.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Pemetrexed is minimally metabolized; it is primarily excreted unchanged in urine via active tubular secretion and glomerular filtration. No significant hepatic metabolism. Enzymes: not extensively metabolized by CYP450.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Approximately 70-90% of the administered dose is excreted unchanged in the urine within 24 hours. Renal elimination is the primary route, with negligible biliary or fecal excretion (<5%).
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Approximately 81-88% bound to plasma proteins, primarily albumin.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
The volume of distribution at steady state is approximately 16.1 L/m² (or roughly 0.4 L/kg based on average body surface area). This low value suggests limited extravascular distribution, consistent with a hydrophilic drug.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Pemetrexed is administered only intravenously; oral bioavailability is not applicable (0% due to lack of oral formulation).
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Cr Cl ≥45 m L/min: No dose adjustment. Cr Cl <45 m L/min: Contraindicated; do not administer. For Cr Cl between 40-79 m L/min, consider dose reduction to 400 mg/m² if prior grade 3/4 toxicity. Monitor Cr Cl prior to each cycle.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Child-Pugh Class A or B: No recommended dose adjustment. Class C: No data; use with caution. Bilirubin >5 times ULN: Avoid use. AST/ALT >5 times ULN: Consider dose reduction to 400 mg/m² if severe transaminase elevation with bilirubin >3 times ULN.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Safety and efficacy not established in pediatric patients. No recommended dose.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
No dose adjustment based on age alone. Monitor renal function (Cr Cl) closely; elderly more likely to have decreased Cr Cl and require dose reduction or discontinuation per renal adjustment criteria. Evaluate for increased risk of myelosuppression and fatigue.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Pemetrexed can cause severe myelosuppression, including severe neutropenia, anemia, and thrombocytopenia. Fatalities have been reported. Patients must have absolute neutrophil count (ANC) ≥1500 cells/mm³ and platelet count ≥100,000 cells/mm³ prior to initiation. Dose reduction or delay is required based on nadir counts.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Bone marrow suppression (dose-dependent); renal toxicity (requires adequate renal function, Cr Cl ≥45 m L/min); gastrointestinal toxicity (nausea, vomiting, mucositis); dermatologic reactions (rash, desquamation); radiation recall; requires folic acid and vitamin B12 supplementation to reduce toxicity; pregnancy category D; fetal harm; hypersensitivity reactions.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
History of severe hypersensitivity reaction to pemetrexed; Cr Cl <45 m L/min for patients with mesothelioma receiving cisplatin; concurrent yellow fever vaccine (live attenuated).
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
No specific dietary restrictions. However, vitamin B12 (from animal products) and folic acid (from leafy greens) are essential supplements. Avoid high-folate foods only if advised by physician (unlikely, as supplementation is required).
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Pemetrexed is teratogenic and embryotoxic in animal studies. In humans, it is contraindicated in pregnancy (FDA Pregnancy Category D). First trimester exposure carries high risk of major congenital malformations, spontaneous abortion, and fetal death. Second and third trimester exposure increases risk of intrauterine growth restriction, oligohydramnios, and fetal myelosuppression.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No data on pemetrexed excretion in human milk. Due to potential for serious adverse reactions in nursing infants (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during treatment and for at least 1 week after last dose. M/P ratio not established.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
No established dosing guidelines in pregnancy due to contraindication. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may reduce drug exposure, but dose adjustments are not recommended because of teratogenicity and lack of safety data. Treatment should be avoided or pregnancy terminated if exposure occurs.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Pemetrexed requires folic acid and vitamin B12 supplementation to reduce hematologic and gastrointestinal toxicity. Administer dexamethasone prophylaxis to prevent skin rash. Contraindicated in patients with creatinine clearance <45 m L/min. Avoid concurrent NSAIDs in patients with mild to moderate renal impairment (Cr Cl 45-79 m L/min) as they may increase pemetrexed toxicity.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
Take folic acid daily and vitamin B12 injections as prescribed to reduce side effects.,Report any skin rash, diarrhea, or mouth sores immediately.,Avoid aspirin and NSAIDs unless approved by your doctor, especially if you have kidney problems.,Stay hydrated and monitor for signs of infection (fever, chills).,Do not skip or stop your vitamin supplements even if you feel well.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
"The risk or severity of adverse effects can be increased when Pemetrexed is combined with Leflunomide."
"Pemetrexed may decrease the cardiotoxic activities of Acetyldigitoxin."
"Pemetrexed may increase the immunosuppressive activities of Fingolimod."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTA vs PEMETREXED FOR INJECTION, answered by our medical review team.
ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. PEMETREXED FOR INJECTION is a Antineoplastic Antifolate that works by Pemetrexed is a folate analog metabolic inhibitor that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent de novo synthesis of thymidine and purine nucleotides, thereby disrupting DNA and RNA synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTA and PEMETREXED FOR INJECTION depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. The standard adult dose of PEMETREXED FOR INJECTION is: 500 mg/m² IV over 10 minutes on Day 1 of each 21-day cycle, in combination with cisplatin 75 mg/m² IV over 2 hours starting 30 minutes after pemetrexed completion. Administer folic acid 350-1000 µg po daily starting 7 days before first dose and continuing until 21 days after last dose, vitamin B12 1000 µg IM 7 days before first dose and every 3 cycles thereafter, and dexamethasone 4 mg po twice daily on day before, day of, and day after pemetrexed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTA and PEMETREXED FOR INJECTION in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. PEMETREXED FOR INJECTION is classified as Category C. Pemetrexed is teratogenic and embryotoxic in animal studies. In humans, it is contraindicated in pregnancy (FDA Pregnancy Category D). First trimester exposure carries high risk of. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.